Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo shows promise in early cancer trial

NCT ID NCT04354246

First seen May 14, 2026 · Last updated May 30, 2026 · Updated 3 times

Summary

This early-stage study tested the safety of a new drug called COM902, given alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, or colon cancer that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. While the drug may help control the cancer, it is not expected to be a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Florida Cancer Specialists

    Sarasota, Florida, 34230, United States

  • Froedtert & Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • MD Anderson Cancer Center.

    Houston, Texas, 77030, United States

  • Mary Crowley Cancer Research

    Dallas, Texas, 75230, United States

  • Massachusetts General Hospital.

    Boston, Massachusetts, 02114, United States

  • START Midwest.

    Grand Rapids, Michigan, 49503, United States

  • The Ohio State University Comprehensive Cancer Center.

    Columbus, Ohio, 43210, United States

  • The START Center for Cancer Care.

    San Antonio, Texas, 78229, United States

  • The University of Tennessee WEST Cancer Center.

    Memphis, Tennessee, 38138, United States

Conditions

The condition(s) this trial relates to.

cancer colonic neoplasm lung neoplasm ovarian cancer plasma cell myeloma plasma cell neoplasm Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.